These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 12500422)

  • 1. [Cardiovascular disease in terminal end-stage renal failure--epidemiological aspects].
    Kessler M
    Nephrologie; 2002; 23(7):361-5. PubMed ID: 12500422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are traditional risk factors valid for assessing cardiovascular risk in end-stage renal failure patients?
    Shah DS; Polkinghorne KR; Pellicano R; Kerr PG
    Nephrology (Carlton); 2008 Dec; 13(8):667-71. PubMed ID: 18761627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kidney transplantation candidates and cardiovascular risk factors.
    Noshad H; Ardalan MR; Mortazavi M; Tayebi H; Safa J; Nezami N
    Transplant Proc; 2007 May; 39(4):871-4. PubMed ID: 17524836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cardiovascular risk in hemodialysis in Spain: prevalence, management and target results (MAR study)].
    Portolés J; López-Gómez JM; Aljama P
    Nefrologia; 2005; 25(3):297-306. PubMed ID: 16053011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inflammation, residual kidney function, and cardiac hypertrophy are interrelated and combine adversely to enhance mortality and cardiovascular death risk of peritoneal dialysis patients.
    Wang AY; Wang M; Woo J; Lam CW; Lui SF; Li PK; Sanderson JE
    J Am Soc Nephrol; 2004 Aug; 15(8):2186-94. PubMed ID: 15284304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cardioprotection: an essential component for predialysis chronic renal failure treatment].
    Jungers P; Qualim Z; Nguyen-Khoa T; Massy Z; London G
    Nephrologie; 2003; 24(2):79-88. PubMed ID: 12723513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cardiovascular risk in patients with chronic renal failure. Patients in renal replacement therapy].
    Cases A; Vera M; López Gómez JM
    Nefrologia; 2002; 22 Suppl 1():68-74. PubMed ID: 11987673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Epidemiology of cardiovascular disease in CKD-MBD].
    Di Micco L; Mozzillo GR; Cianciaruso B
    G Ital Nefrol; 2009; 26 Suppl 49():S3-10. PubMed ID: 19941272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of cardiovascular death in ESRD.
    Zoccali C; Tripepi G; Mallamaci F
    Semin Nephrol; 2005 Nov; 25(6):358-62. PubMed ID: 16298255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular disease in the dialysis population: prognostic significance of arterial disorders.
    Guérin AP; Pannier B; Marchais SJ; London GM
    Curr Opin Nephrol Hypertens; 2006 Mar; 15(2):105-10. PubMed ID: 16481874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of cardiovascular risk factors and complications before and after kidney transplantation.
    Fazelzadeh A; Mehdizadeh A; Ostovan MA; Raiss-Jalali GA
    Transplant Proc; 2006 Mar; 38(2):506-8. PubMed ID: 16549161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidemiology of cardiovascular risk factors in chronic renal disease.
    Coresh J; Longenecker JC; Miller ER; Young HJ; Klag MJ
    J Am Soc Nephrol; 1998 Dec; 9(12 Suppl):S24-30. PubMed ID: 11443765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Diamant Alpin Dialysis cohort study: clinico-biological characteristics and cardiovascular genetic risk profile of incident patients.
    Pernod G; Bosson JL; Golshayan D; Barro C; Alloatti S; Turc-Baron C; Quarello F; Jeantet A; Von Albertini B; Forêt M; Lauren G; Cordonnier D; Piccoli G; Wauters JP;
    J Nephrol; 2004; 17(1):66-75. PubMed ID: 15151261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
    Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
    Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Characteristics of hyperhomocysteinemia in dialysis patients].
    Lovcić V; Kes P; Reiner Z
    Acta Med Croatica; 2006; 60(1):21-6. PubMed ID: 16802568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidemiology of cardiovascular disease in chronic renal disease.
    Foley RN; Parfrey PS; Sarnak MJ
    J Am Soc Nephrol; 1998 Dec; 9(12 Suppl):S16-23. PubMed ID: 11443763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Homocysteine as a risk factor for cardiovascular disease in patients treated by dialysis: a meta-analysis.
    Heinz J; Kropf S; Luley C; Dierkes J
    Am J Kidney Dis; 2009 Sep; 54(3):478-89. PubMed ID: 19359080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidemiological aspects of cardiovascular disease in the elderly.
    Fletcher AE; Bulpitt CJ
    J Hypertens Suppl; 1992 Apr; 10(2):S51-8. PubMed ID: 1593303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of cardiovascular events in patients with end-stage renal disease: an analysis from the Fosinopril in dialysis study.
    Kessler M; Zannad F; Lehert P; Grünfeld JP; Thuilliez C; Leizorovicz A; Lechat P;
    Nephrol Dial Transplant; 2007 Dec; 22(12):3573-9. PubMed ID: 17611249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma homocysteine levels and cardiovascular mortality in patients with end-stage renal disease.
    Buccianti G; Baragetti I; Bamonti F; Furiani S; Dorighet V; Patrosso C
    J Nephrol; 2004; 17(3):405-10. PubMed ID: 15365961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.